Healthcare
The Consequences of Slashing Medicaid Spending
Congressional Republicans are looking to make deep budget cuts, and Medicaid spending is a target. Yale SOM’s Dr. Howard Forman says that large-scale reductions in the program would hit the poorest states and the most vulnerable Americans especially hard.
Has Employment Become the Goal of the U.S. Healthcare System?
Dr. Greg Licholai writes that the complexity of the healthcare system has generated unexpected incentives—one of which is that we have come to rely on the industry for jobs.
Prof. Fiona Scott Morton Outlines Fixes for Healthcare Markets in Congressional Testimony
Prof. Scott Morton called a private healthcare system without competitive pressure “the worst of both worlds” in terms of costs.
Big Issues: The Foundations of Public Health
Yale physician Elijah Paintsil joined the Global Leadership: Big Issues class to describe the history of public health and how it informs current efforts to establish a minimum global standard for healthcare.
For U.S. Army, Improving Mental Health Care Meant Breaking Down Barriers Between Teams
The study suggests that for many organizations, assigning professionals from one team as points of contact to members of another—while they still maintain close ties to their own peers—may help resolve conflicts.
Research-Based Tips for a Better New Year
What does the data say about making the most of 2019? We asked Yale SOM faculty to share self-improvement tips based on their research.
Danguole Altman ’85 on Career and Family
Danguole Altman ’85, founder of Vapogenix, on the choices she made as she led multiple companies and raised a family.
Three Questions: Prof. Jason Abaluck on Short-Term Health Insurance
We asked Yale SOM health economist Jason Abaluck how the expansion of low-cost, short-term insurance could affect consumers and the insurance markets.
Is CRISPR Worth the Risk?
Dr. Greg Licholai, a biotech entrepreneur and a lecturer at Yale SOM, explains the gene-editing technology’s potential and its dangers.
Three Questions: Dr. Greg Licholai on Biotech After Theranos
We asked Dr. Greg Licholai, a lecturer at Yale SOM and and a biotech entrepreneur, what other healthcare startups can learn from the Theranos debacle.
Do Companies Buy Competitors in Order to Shut Them Down?
A study co-authored by Yale SOM researchers Florian Ederer and Song Ma suggests that “killer acquisitions” by pharmaceutical companies are potentially limiting the number of new treatments available.
